Bicara Therapeutics Financials

No, Bicara Therapeutics (BCAX) reported a net income of -$137.9M in fiscal year 2025.

Bicara Therapeutics (BCAX) reported diluted earnings per share of $-2.52 for fiscal year 2025. This represents a 37.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bicara Therapeutics (BCAX) had EBITDA of -$155.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Bicara Therapeutics (BCAX) has a return on equity of -34.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Bicara Therapeutics (BCAX) generated -$107.1M in free cash flow during fiscal year 2025. This represents a -43.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Bicara Therapeutics (BCAX) generated -$106.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Bicara Therapeutics (BCAX) had $431.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Bicara Therapeutics (BCAX) invested $280K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Bicara Therapeutics (BCAX) invested $18.7M in research and development during fiscal year 2025.

Bicara Therapeutics (BCAX) had 65M shares outstanding as of fiscal year 2025.

Bicara Therapeutics (BCAX) had a current ratio of 14.58 as of fiscal year 2025, which is generally considered healthy.

Bicara Therapeutics (BCAX) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Bicara Therapeutics (BCAX) had a return on assets of -32.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Bicara Therapeutics (BCAX) had $96.7M in cash against an annual operating cash burn of $106.8M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Bicara Therapeutics (BCAX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Bicara Therapeutics (BCAX) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.